BriaCell Therapeutics Raises $13.8 Million in Public Offering to Advance Cancer Immunotherapy Research
TL;DR
BriaCell Therapeutics announced a public offering of 3,066,666 units at $4.50 per unit for gross proceeds of $13.8 million.
Each unit includes one common share or pre-funded warrant and one warrant exercisable at $5.25 per share, led by ThinkEquity.
BriaCell plans to use the net proceeds for working capital, corporate purposes, and advancing business objectives in cancer care.
InvestorWire is a specialized communications platform focusing on press release syndication for private and public companies.
Found this article helpful?
Share it with your network and spread the knowledge!
BriaCell Therapeutics has successfully priced a public offering of 3,066,666 units at $4.50 per unit, generating gross proceeds of approximately $13.8 million. The offering, led by ThinkEquity, is expected to close on April 28, 2025, pending standard market conditions.
Each unit in the offering comprises one common share or pre-funded warrant and one warrant exercisable at $5.25 per share. The company plans to allocate the net proceeds toward working capital, corporate purposes, and advancing its strategic business objectives in cancer immunotherapy research.
The capital raise represents a significant milestone for BriaCell, a clinical-stage biotechnology firm focused on developing novel immunotherapies to transform cancer treatment. By securing substantial funding, the company can continue its research and development efforts, potentially bringing innovative cancer treatments closer to clinical application.
Investors and industry observers will likely view this financing as a positive signal of the company's commitment to advancing cutting-edge cancer research and its potential to make meaningful contributions to oncology treatment options.
Curated from InvestorBrandNetwork (IBN)
